BioSpace News Archive

Global life sciences supplier Cayman Chemical (Cayman) announced today a strategic partnership with Navinci Diagnostics (Navinci), a Swedish biotechnology company developing innovative tools for spatial proteomics.

Children’s Hospital of Philadelphia has been recognized by the 2023 Disability Equality Index as a leader in “Best Places to Work for Disability Inclusion.” The DEI is the nation’s most comprehensive annual benchmarking tool used to survey employers’ disability policies, practices, and initiatives.

Neurocrine Biosciences, Inc. announced that it has scheduled its second quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time on August 1, 2023.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, announced the appointment of Habib Dable as a member of Aerovate’s Board of Directors.

Arthrosi Therapeutics, a clinical-stage biotechnology company, announced the successful securing of $75 million in Series D financing.

ReWalk Robotics Ltd. announced Larry Jasinski, Chief Executive Officer, will present virtually at the Emerging Growth Conference at 10:15 am EDT on Wednesday, July 12, 2023.

Verve Medical, Inc. (Verve) announced today that the Company has received approval from the US Food & Drug Administration (FDA) to initiate its Natural Orifice via renal pelvis denervation (NOVEL- Denervation) Pivotal IDE trial for the treatment of uncontrolled hypertension to lower blood pressure.

Eisai Co. Ltd announced that the company will present the latest findings on its Alzheimer’s disease pipeline and research, including Eisai’s anti-amyloid beta protofibril* antibody for the treatment of Alzheimer’s disease, lecanemab, and the company’s investigational anti-MTBR** tau antibody, E2814, at the Alzheimer’s Association International Conference.

Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with axitinib for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma, has been accepted by the National Medical Products Administration.

The National University of Singapore Centre for Governance and Sustainability and PricewaterhouseCoopers Singapore recently jointly released Sustainability Counts II.